Testosterone for Life

Testosterone for Life argues that testosterone deficiency in men is common, frequently missed, and readily treatable, and that the decades-old belief that testosterone therapy fuels prostate cancer is not supported by the evidence. That second claim is the reason the book mattered, because that fear kept many symptomatic men untreated.

Morgentaler's central mechanism is the saturation model. Androgen receptors in prostate tissue are, on his account, saturated at relatively low testosterone concentrations, so raising levels above that threshold adds no further stimulus to prostate tissue. He pairs this with a clinical argument: symptoms of low testosterone — fatigue, low libido, erectile difficulty, loss of muscle, low mood — are non-specific, get attributed to normal aging, and are often not investigated at all.

The book is written for men with those symptoms and for clinicians who want the counterargument to a long-standing prohibition set out plainly by someone who has treated and published in the area.

On where it sits: the prostate argument has gained considerable ground since 2008 and is reflected in more permissive current guidance, though it is not universally accepted and does not extend to men with active prostate cancer. The book's age matters elsewhere. It predates the large randomised cardiovascular safety trial reported in 2023, which was reassuring on major cardiac events in men with confirmed deficiency, and it predates current diagnostic standards on repeat morning testing and free testosterone. Testosterone therapy is prescription-only in Canada, and guidelines set the indication as confirmed biochemical deficiency together with consistent symptoms — not low-normal levels in an otherwise well man. Treatment suppresses fertility, can raise red cell mass, and requires ongoing monitoring. The optimisation framing common online runs well ahead of what any guideline supports, and this book should not be read as licence for it.